Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-03-24
DOI
10.3389/fonc.2020.00384
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer
- (2019) Nikolas Tim Martin et al. Scientific Reports
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
- (2019) Xuefei Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
- (2019) Tae Jin Lee et al. MOLECULAR CANCER THERAPEUTICS
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Recent advances in nanotheranostics for triple negative breast cancer treatment
- (2019) Vikram Thakur et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
- (2018) Stephen J. Russell et al. CANCER CELL
- Abstract OT2-07-01: Phase 1/2 trial of the oncolytic virus, talimogene laherparpvec, in combination with neoadjuvant chemotherapy in stage II/III triple negative breast cancer
- (2018) HH Soliman et al. CANCER RESEARCH
- Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
- (2018) Dipongkor Saha et al. CLINICAL CANCER RESEARCH
- Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
- (2018) Pedro Berraondo et al. CLINICAL CANCER RESEARCH
- Myeloid derived-suppressor cells: their role in cancer and obesity
- (2018) Suzanne Ostrand-Rosenberg CURRENT OPINION IN IMMUNOLOGY
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses
- (2018) Kristen N. Balogh et al. PLoS One
- Metastatic and triple-negative breast cancer: challenges and treatment options
- (2018) Sumayah Al-Mahmood et al. Drug Delivery and Translational Research
- Oncolytic Virotherapy for Breast Cancer Treatment
- (2018) Samia M. O’Bryan et al. CURRENT GENE THERAPY
- KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
- (2018) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
- (2018) Anastasia Constantinidou et al. PHARMACOLOGY & THERAPEUTICS
- Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs
- (2018) Anna Diana et al. Current Oncology Reports
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
- (2017) Purnima Bhat et al. Cell Death & Disease
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
- (2016) Praveen K. Bommareddy et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer
- (2016) L. Cicchelero et al. Veterinary and Comparative Oncology
- A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
- (2016) Xilin Chen et al. Oncotarget
- Oncolytic herpes simplex virus interactions with the host immune system
- (2016) Dipongkor Saha et al. Current Opinion in Virology
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
- (2015) Alessandra Cesano Journal for ImmunoTherapy of Cancer
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer
- (2014) S Gholami et al. CANCER GENE THERAPY
- Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus
- (2014) Slawomir Antoszczyk et al. NEURO-ONCOLOGY
- Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
- (2013) T. A. Cheema et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncolytic herpes simplex virus treatment of metastatic breast cancer
- (2011) Renbin Liu INTERNATIONAL JOURNAL OF ONCOLOGY
- The emerging role of CXCL10 in cancer (Review)
- (2011) MINGLI LIU et al. Oncology Letters
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More